{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05594563",
            "orgStudyIdInfo": {
                "id": "4-SRA-2022-1205-M-B"
            },
            "organization": {
                "fullName": "Indiana University",
                "class": "OTHER"
            },
            "briefTitle": "TArgeting Type 1 Diabetes Using POLyamines (TADPOL)",
            "officialTitle": "TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes",
            "acronym": "TADPOL",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "targeting-type-diabetes-using-polyamines-tadpol"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-12",
            "studyFirstSubmitQcDate": "2022-10-21",
            "studyFirstPostDateStruct": {
                "date": "2022-10-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-30",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Emily K. Sims",
                "investigatorTitle": "Associate Professor of Pediatrics",
                "investigatorAffiliation": "Indiana University School of Medicine"
            },
            "leadSponsor": {
                "name": "Emily K. Sims",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Juvenile Diabetes Research Foundation",
                    "class": "OTHER"
                },
                {
                    "name": "Cancer Prevention Pharmaceuticals, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\\[s\\] it aims to answer are:\n\n* Does it reduce stress on the cells that make insulin?\n* Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits will include blood draws urine collection and other tests.",
            "detailedDescription": "This study will be a multicenter, double-blind, placebo-controlled, 2:1 random assigned, phase II clinical trial for individuals with recent onset type 1 diabetes. The investigators are conducting a double masked placebo-controlled intention to treat study enrolling persons with new onset T1D with documented continued residual C-peptide production. Within 45 days of screening and a run-in period during which eligibility will be determined and glycemic control optimized, subjects will have a 6-month double-masked treatment period with either DFMO or placebo. After a 6-month wash-out period the durability of effect will be assessed. Subjects will be randomly assigned either 1000mg/m2/day oral DFMO or placebo treatment at a 2:1 ratio."
        },
        "conditionsModule": {
            "conditions": [
                "Type 1 Diabetes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Subject are randomized to either treatment or placebo arm.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Participant, Care provider and Investigator blinded",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Arm",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Difluoromethylornithine (DFMO) pill ,1000mg/m2/day, for 6 months",
                    "interventionNames": [
                        "Drug: DFMO"
                    ]
                },
                {
                    "label": "Placebo Arm",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo pill taken twice a day orally for 6 months",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DFMO",
                    "description": "DFMO orally twice a day",
                    "armGroupLabels": [
                        "Treatment Arm"
                    ],
                    "otherNames": [
                        "Difluoromethylornithine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo orally twice a day",
                    "armGroupLabels": [
                        "Placebo Arm"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinical efficacy of 1000 mg/m2/day of oral DFMO after 6 months of treatment",
                    "description": "Primary endpoint defining clinical efficacy will be based on mixed-meal stimulated C-peptide area under the curve (AUC; in arbitrary units) in the treatment group compared to placebo after 6 months of DFMO treatment",
                    "timeFrame": "6 month"
                },
                {
                    "measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v5",
                    "description": "A summary of serious and non-serious adverse events (AEs) will be reported.",
                    "timeFrame": "through study completion, an average of one year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Clinical efficacy of 1000 mg/m2/day of oral DFMO after 3 months of treatment, 9 months after treatment (or 3 months after treatment end), and 12 months after treatment (or 6 months after treatment end).",
                    "description": "Secondary endpoints will be based on mixed meal stimulated C-peptide AUC (arbitrary units) at 3 months after treatment, 9 months after treatment, and 12 months after treatment.",
                    "timeFrame": "through study completion, an average of one year"
                },
                {
                    "measure": "Decrease in urinary polyamides after 6 months of DFMO treatment.",
                    "description": "Decrease in urinary putrescine (in umol/g Cr) from baseline after 6 months of DFMO treatment, measured using high performance liquid chromatography.",
                    "timeFrame": "up to 24 weeks after treatment"
                },
                {
                    "measure": "Biomarkers of \u03b2 cell stress at 3, 6, 9, and 12 months after treatment.",
                    "description": "Fasting and stimulated proinsulin/c-peptide ratios (%) will be measured using immunoassays and reported at baseline, 3 months after treatment, 6 months after treatment, 9 months after treatment, and 12 months after treatment.",
                    "timeFrame": "through study completion, an average of one year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Males and females 6- \u226540 years of age with a clinical diagnosis of T1D\n2. T1D clinical diagnosis with insulin start date no more than 100 days prior to the time of randomization\n3. Random non-fasting C-peptide level of \\>0.2 pmol/mL (equivalent to \\>0.6ng/ml) at screening.\n4. Positive for any one of the following diabetes-related autoantibodies (IAA, GAA, IA-2, or ZnT8)\n5. Treatment na\u00efve of any immunomodulatory agent\n6. Normal hearing at screening, defined as acceptable results of pure-tone audiometry (\\<20 decibel \\[dB\\] baseline thresholds for frequencies 250, 500, 1000, and 2000 Hz\n\nExclusion Criteria:\n\n1. Presence of severe, active disease that interferes with dietary intake or requires the use of chronic medication, with the exception of well-controlled hypothyroidism and mild asthma not requiring oral steroids. Presence of any psychiatric disorder that will affect ability to participate in study.\n2. Diabetes other than T1D\n3. Chronic illness known to affect glucose metabolism (e.g. Cushing syndrome, polycystic ovarian disorder, cystic fibrosis) or taking medications that affect glucose metabolism (e.g. steroids, metformin)\n4. Inability to swallow pills\n5. Psychiatric impairment or current use of anti-psychotic medication\n6. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.\n7. Neutropenia (\\< 1,500 neutrophils/\u03bcL)\n8. Leukopenia (\\< 3,000 leukocytes /\u03bcL)\n9. Lymphopenia ( \\< 800 lymphocytes/\u03bcL)\n10. Thrombocytopenia (\\<100,000 platelets/\u03bcL)\n11. Clinically significant anemia or Hemoglobin as defined below:\n\n    In Adults: Hgb \\<12.0g/dL in females and \\<13.0g/dL in males In Children: 12- \\<18: \\<11.4 g/dL in females and \\<12.4 g/dL in males In Children: 6- \\<12: Hgb \\<11.2 g/dL\n12. Impaired renal function (assessed by history and BUN/Creatinine, DFMO is renally excreted)\n13. Allergy to milk or soy (components of Boost\u00ae drink used for mixed meal tolerance testing)\n14. Female participants of child-bearing age with reproductive potential, must not be pregnant and agree to use 2 effective forms of birth control or be abstinent during the study period (see below). Male participants (including men who have had vasectomies) whose partners are pregnant or may be pregnant should use condoms while on study drug, until 2 weeks after discontinuation of drug, while the partner is pregnant.\n15. Active seizure disorder, defined as requiring chronic medication at the time of study or having had a seizure within the past 12 months at the time of screening\n16. Enrollment into another intervention trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "4 Years",
            "maximumAge": "40 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Maria L Spall, BSN",
                    "role": "CONTACT",
                    "phone": "317-278-7034",
                    "email": "malnicho@iu.edu"
                },
                {
                    "name": "Operations Manager",
                    "role": "CONTACT",
                    "phone": "317-278-8879",
                    "email": "tadpol@iu.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Emily K Sims, MD,MS",
                    "affiliation": "Indiana University School of Medicine",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Barbara Davis Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lexie Chesshir, RN",
                            "role": "CONTACT",
                            "phone": "303-724-1755",
                            "email": "lexie.chesshir@cuanschutz.edu"
                        },
                        {
                            "name": "Kimber Simmons, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Triniece Pearson, PhD,RN",
                            "role": "CONTACT",
                            "phone": "773-359-7556",
                            "email": "tpearson1@medicine.bsd.uchicago.edu"
                        },
                        {
                            "name": "Siri Greeley, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "IU Health Riley Hospital for Children",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Moreau M Ryan",
                            "role": "CONTACT",
                            "phone": "317-278-7037",
                            "email": "elmryan@iu.edu"
                        },
                        {
                            "name": "T1D Research",
                            "role": "CONTACT",
                            "phone": "317-278-8879",
                            "email": "tadpol@iu.edu"
                        },
                        {
                            "name": "Emily K Sims, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Linda A DiMeglio, MD, MPH",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Children's Mercy Hospital",
                    "status": "RECRUITING",
                    "city": "Kansas City",
                    "state": "Kansas",
                    "zip": "64108",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Britt Schmalzbach, RN",
                            "role": "CONTACT",
                            "phone": "816-460-1097",
                            "email": "endoclinicaltrials@cmh.edu"
                        },
                        {
                            "name": "Mark Clements, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.11417,
                        "lon": -94.62746
                    }
                },
                {
                    "facility": "University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aimee Katona",
                            "role": "CONTACT",
                            "phone": "734-615-4079",
                            "email": "PEDS-ENDO-DM-Research@med.umich.edu"
                        },
                        {
                            "name": "Inas Thomas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joanne Kramer, BS",
                            "role": "CONTACT",
                            "phone": "414-955-8486",
                            "email": "T1Dinfo@mcw.edu"
                        },
                        {
                            "name": "Susanne Cabrera, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "22116709",
                    "type": "BACKGROUND",
                    "citation": "Brooks WH. Autoimmune diseases and polyamines. Clin Rev Allergy Immunol. 2012 Feb;42(1):58-70. doi: 10.1007/s12016-011-8290-y."
                },
                {
                    "pmid": "15221502",
                    "type": "BACKGROUND",
                    "citation": "Seiler N. Catabolism of polyamines. Amino Acids. 2004 Jun;26(3):217-33. doi: 10.1007/s00726-004-0070-z. Epub 2004 Apr 20."
                },
                {
                    "pmid": "23221207",
                    "type": "BACKGROUND",
                    "citation": "Jeter JM, Alberts DS. Difluoromethylornithine: the proof is in the polyamines. Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429."
                },
                {
                    "pmid": "20670594",
                    "type": "BACKGROUND",
                    "citation": "Maier B, Tersey SA, Mirmira RG. Hypusine: a new target for therapeutic intervention in diabetic inflammation. Discov Med. 2010 Jul;10(50):18-23."
                },
                {
                    "pmid": "7632663",
                    "type": "BACKGROUND",
                    "citation": "Bardocz S, Duguid TJ, Brown DS, Grant G, Pusztai A, White A, Ralph A. The importance of dietary polyamines in cell regeneration and growth. Br J Nutr. 1995 Jun;73(6):819-28. doi: 10.1079/bjn19950087."
                },
                {
                    "pmid": "21460598",
                    "type": "BACKGROUND",
                    "citation": "Renaudineau Y, Youinou P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio J Med. 2011;60(1):10-6. doi: 10.2302/kjm.60.10."
                },
                {
                    "pmid": "1438532",
                    "type": "BACKGROUND",
                    "citation": "McCann PP, Pegg AE. Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992;54(2):195-215. doi: 10.1016/0163-7258(92)90032-u."
                },
                {
                    "pmid": "20127992",
                    "type": "RESULT",
                    "citation": "Hong SK, Chaturvedi R, Piazuelo MB, Coburn LA, Williams CS, Delgado AG, Casero RA Jr, Schwartz DA, Wilson KT. Increased expression and cellular localization of spermine oxidase in ulcerative colitis and relationship to disease activity. Inflamm Bowel Dis. 2010 Sep;16(9):1557-66. doi: 10.1002/ibd.21224."
                },
                {
                    "pmid": "20501948",
                    "type": "RESULT",
                    "citation": "Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, Chakrabarti SK, Nunemaker CS, Stull ND, Taylor CA, Thompson JE, Dondero RS, Lewis EC, Dinarello CA, Nadler JL, Mirmira RG. The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice. J Clin Invest. 2010 Jun;120(6):2156-70. doi: 10.1172/JCI38924. Epub 2010 May 24."
                },
                {
                    "pmid": "21389784",
                    "type": "RESULT",
                    "citation": "Templin AT, Maier B, Nishiki Y, Tersey SA, Mirmira RG. Deoxyhypusine synthase haploinsufficiency attenuates acute cytokine signaling. Cell Cycle. 2011 Apr 1;10(7):1043-9. doi: 10.4161/cc.10.7.15206. Epub 2011 Apr 1."
                },
                {
                    "pmid": "20405312",
                    "type": "RESULT",
                    "citation": "Bjelakovic G, Beninati S, Bjelakovic B, Sokolovic D, Jevtovic T, Stojanovic I, Rossi S, Tabolacci C, Kocic G, Pavlovic D, Saranac Lj, Zivic S. Does polyamine oxidase activity influence the oxidative metabolism of children who suffer of diabetes mellitus? Mol Cell Biochem. 2010 Aug;341(1-2):79-85. doi: 10.1007/s11010-010-0439-0. Epub 2010 Apr 20."
                },
                {
                    "pmid": "23250488",
                    "type": "RESULT",
                    "citation": "Nishiki Y, Adewola A, Hatanaka M, Templin AT, Maier B, Mirmira RG. Translational control of inducible nitric oxide synthase by p38 MAPK in islet beta-cells. Mol Endocrinol. 2013 Feb;27(2):336-49. doi: 10.1210/me.2012-1230. Epub 2012 Dec 18."
                },
                {
                    "pmid": "19968980",
                    "type": "RESULT",
                    "citation": "Higashi K, Yoshida M, Igarashi A, Ito K, Wada Y, Murakami S, Kobayashi D, Nakano M, Sohda M, Nakajima T, Narita I, Toida T, Kashiwagi K, Igarashi K. Intense correlation between protein-conjugated acrolein and primary Sjogren's syndrome. Clin Chim Acta. 2010 Mar;411(5-6):359-63. doi: 10.1016/j.cca.2009.11.032. Epub 2009 Dec 5."
                },
                {
                    "pmid": "8295175",
                    "type": "RESULT",
                    "citation": "Furumitsu Y, Yukioka K, Kojima A, Yukioka M, Shichikawa K, Ochi T, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H. Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol. 1993 Oct;20(10):1661-5."
                },
                {
                    "pmid": "10852253",
                    "type": "RESULT",
                    "citation": "Furumitsu Y, Yukioka K, Yukioka M, Ochi T, Morishima Y, Matsui-Yuasa I, Otani S, Inaba M, Nishizawa Y, Morii H. Interleukin-1beta induces elevation of spermidine/spermine N1-acetyltransferase activity and an increase in the amount of putrescine in synovial adherent cells from patients with rheumatoid arthritis. J Rheumatol. 2000 Jun;27(6):1352-7."
                },
                {
                    "pmid": "17524725",
                    "type": "RESULT",
                    "citation": "Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW, Meyskens FL Jr. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc. 2007 Jun;107(6):1024-7. doi: 10.1016/j.jada.2007.03.012."
                },
                {
                    "pmid": "11564949",
                    "type": "RESULT",
                    "citation": "Milovic V. Polyamines in the gut lumen: bioavailability and biodistribution. Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1021-5. doi: 10.1097/00042737-200109000-00004."
                },
                {
                    "pmid": "19763038",
                    "type": "RESULT",
                    "citation": "Soda K, Kano Y, Sakuragi M, Takao K, Lefor A, Konishi F. Long-term oral polyamine intake increases blood polyamine concentrations. J Nutr Sci Vitaminol (Tokyo). 2009 Aug;55(4):361-6. doi: 10.3177/jnsv.55.361."
                },
                {
                    "pmid": "11208527",
                    "type": "RESULT",
                    "citation": "Sjoholm A, Arkhammar P, Berggren PO, Andersson A. Polyamines in pancreatic islets of obese-hyperglycemic (ob/ob) mice of different ages. Am J Physiol Cell Physiol. 2001 Feb;280(2):C317-23. doi: 10.1152/ajpcell.2001.280.2.C317."
                },
                {
                    "pmid": "8408643",
                    "type": "RESULT",
                    "citation": "Sjoholm A, Arkhammar P, Welsh N, Bokvist K, Rorsman P, Hallberg A, Nilsson T, Welsh M, Berggren PO. Enhanced stimulus-secretion coupling in polyamine-depleted rat insulinoma cells. An effect involving increased cytoplasmic Ca2+, inositol phosphate generation, and phorbol ester sensitivity. J Clin Invest. 1993 Oct;92(4):1910-7. doi: 10.1172/JCI116784."
                },
                {
                    "pmid": "18176934",
                    "type": "RESULT",
                    "citation": "Roy UK, Rial NS, Kachel KL, Gerner EW. Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog. 2008 Jul;47(7):538-53. doi: 10.1002/mc.20414."
                },
                {
                    "pmid": "12972423",
                    "type": "RESULT",
                    "citation": "Belting M, Mani K, Jonsson M, Cheng F, Sandgren S, Jonsson S, Ding K, Delcros JG, Fransson LA. Glypican-1 is a vehicle for polyamine uptake in mammalian cells: a pivital role for nitrosothiol-derived nitric oxide. J Biol Chem. 2003 Nov 21;278(47):47181-9. doi: 10.1074/jbc.M308325200. Epub 2003 Sep 11."
                },
                {
                    "pmid": "10024506",
                    "type": "RESULT",
                    "citation": "Belting M, Persson S, Fransson LA. Proteoglycan involvement in polyamine uptake. Biochem J. 1999 Mar 1;338 ( Pt 2)(Pt 2):317-23."
                },
                {
                    "pmid": "18360702",
                    "type": "RESULT",
                    "citation": "Welch JE, Bengtson P, Svensson K, Wittrup A, Jenniskens GJ, Ten Dam GB, Van Kuppevelt TH, Belting M. Single chain fragment anti-heparan sulfate antibody targets the polyamine transport system and attenuates polyamine-dependent cell proliferation. Int J Oncol. 2008 Apr;32(4):749-56."
                },
                {
                    "pmid": "16714282",
                    "type": "RESULT",
                    "citation": "Nevins AK, Thurmond DC. Caveolin-1 functions as a novel Cdc42 guanine nucleotide dissociation inhibitor in pancreatic beta-cells. J Biol Chem. 2006 Jul 14;281(28):18961-72. doi: 10.1074/jbc.M603604200. Epub 2006 May 19."
                },
                {
                    "pmid": "19997760",
                    "type": "RESULT",
                    "citation": "Park MH, Nishimura K, Zanelli CF, Valentini SR. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids. 2010 Feb;38(2):491-500. doi: 10.1007/s00726-009-0408-7. Epub 2009 Dec 8."
                },
                {
                    "pmid": "20956533",
                    "type": "RESULT",
                    "citation": "Robbins RD, Tersey SA, Ogihara T, Gupta D, Farb TB, Ficorilli J, Bokvist K, Maier B, Mirmira RG. Inhibition of deoxyhypusine synthase enhances islet beta cell function and survival in the setting of endoplasmic reticulum stress and type 2 diabetes. J Biol Chem. 2010 Dec 17;285(51):39943-52. doi: 10.1074/jbc.M110.170142. Epub 2010 Oct 18."
                },
                {
                    "pmid": "7895500",
                    "type": "RESULT",
                    "citation": "Packham G, Cleveland JL. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr Top Microbiol Immunol. 1995;194:283-90. doi: 10.1007/978-3-642-79275-5_33."
                },
                {
                    "pmid": "22442300",
                    "type": "RESULT",
                    "citation": "Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, Colvin SC, Evans-Molina C, Rickus JL, Maier B, Mirmira RG. Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes. 2012 Apr;61(4):818-27. doi: 10.2337/db11-1293."
                },
                {
                    "pmid": "26397425",
                    "type": "RESULT",
                    "citation": "Watkins RA, Evans-Molina C, Terrell JK, Day KH, Guindon L, Restrepo IA, Mirmira RG, Blum JS, DiMeglio LA. Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Transl Res. 2016 Feb;168:96-106.e1. doi: 10.1016/j.trsl.2015.08.010. Epub 2015 Sep 4."
                },
                {
                    "pmid": "15972654",
                    "type": "RESULT",
                    "citation": "Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F. Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. J Immunol. 2005 Jul 1;175(1):237-45. doi: 10.4049/jimmunol.175.1.237."
                },
                {
                    "pmid": "10433086",
                    "type": "RESULT",
                    "citation": "Hsu HC, Thomas T, Sigal LH, Thomas TJ. Polyamine-fas interactions: inhibition of polyamine biosynthesis in MRL-lpr/lpr mice is associated with the up-regulation of fas mRNA in thymocytes. Autoimmunity. 1999;29(4):299-309. doi: 10.3109/08916939908994750."
                },
                {
                    "pmid": "6422008",
                    "type": "RESULT",
                    "citation": "Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis. J Clin Oncol. 1984 Feb;2(2):124-30. doi: 10.1200/JCO.1984.2.2.124."
                },
                {
                    "pmid": "2891995",
                    "type": "RESULT",
                    "citation": "Pepin J, Milord F, Guern C, Schechter PJ. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. Lancet. 1987 Dec 19;2(8573):1431-3. doi: 10.1016/s0140-6736(87)91131-7."
                },
                {
                    "pmid": "17214730",
                    "type": "RESULT",
                    "citation": "Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, Schrode K; Eflornithine HCl Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007 Jan;46(1):94-8. doi: 10.1111/j.1365-4632.2006.03079.x. No abstract available."
                },
                {
                    "pmid": "19188144",
                    "type": "RESULT",
                    "citation": "Gerner EW, Meyskens FL Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009 Feb 1;15(3):758-61. doi: 10.1158/1078-0432.CCR-08-2235."
                },
                {
                    "pmid": "32391579",
                    "type": "RESULT",
                    "citation": "Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 Dec 1;147(11):3152-3159. doi: 10.1002/ijc.33044. Epub 2020 May 24."
                },
                {
                    "pmid": "3093066",
                    "type": "RESULT",
                    "citation": "Bowlin TL, McKown BJ, Davis GF, Sunkara PS. Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-bearing mice. Cancer Res. 1986 Nov;46(11):5494-8."
                },
                {
                    "pmid": "11815483",
                    "type": "RESULT",
                    "citation": "Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes. 2002 Feb;51 Suppl 1:S221-6. doi: 10.2337/diabetes.51.2007.s221."
                },
                {
                    "pmid": "34214479",
                    "type": "RESULT",
                    "citation": "Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA; Gleevec Trial Study Group. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 Aug;9(8):502-514. doi: 10.1016/S2213-8587(21)00139-X. Epub 2021 Jun 29."
                },
                {
                    "type": "RESULT",
                    "citation": "Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP: Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogs. Journal of the American Chemical Society 1978;100:2551-2553"
                },
                {
                    "pmid": "1730582",
                    "type": "RESULT",
                    "citation": "Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J Biol Chem. 1992 Jan 5;267(1):150-8."
                },
                {
                    "pmid": "3105526",
                    "type": "RESULT",
                    "citation": "Pegg AE, McGovern KA, Wiest L. Decarboxylation of alpha-difluoromethylornithine by ornithine decarboxylase. Biochem J. 1987 Jan 1;241(1):305-7. doi: 10.1042/bj2410305."
                },
                {
                    "pmid": "9719479",
                    "type": "RESULT",
                    "citation": "Selamnia M, Mayeur C, Robert V, Blachier F. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol. 1998 Apr 15;55(8):1241-5. doi: 10.1016/s0006-2952(97)00572-8."
                },
                {
                    "pmid": "431333",
                    "type": "RESULT",
                    "citation": "Danzin C, Jung MJ, Grove J, Bey P. Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues. Life Sci. 1979 Feb 5;24(6):519-24. doi: 10.1016/0024-3205(79)90173-5. No abstract available."
                },
                {
                    "pmid": "6781187",
                    "type": "RESULT",
                    "citation": "Oredsson S, Anehus S, Heby O. Inhibition of cell proliferation by DL-alpha-difluoromethylornithine, a catalytic irreversible inhibitor of ornithine decarboxylase. Acta Chem Scand B. 1980;34(6):457-8. doi: 10.3891/acta.chem.scand.34b-0457. No abstract available."
                },
                {
                    "pmid": "8262968",
                    "type": "RESULT",
                    "citation": "Pena A, Reddy CD, Wu S, Hickok NJ, Reddy EP, Yumet G, Soprano DR, Soprano KJ. Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. J Biol Chem. 1993 Dec 25;268(36):27277-85."
                },
                {
                    "pmid": "8356088",
                    "type": "RESULT",
                    "citation": "Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8. doi: 10.1073/pnas.90.16.7804."
                },
                {
                    "pmid": "3128541",
                    "type": "RESULT",
                    "citation": "Celano P, Baylin SB, Giardiello FM, Nelkin BD, Casero RA Jr. Effect of polyamine depletion on c-myc expression in human colon carcinoma cells. J Biol Chem. 1988 Apr 25;263(12):5491-4."
                },
                {
                    "pmid": "10605821",
                    "type": "RESULT",
                    "citation": "Tabib A, Bachrach U. Role of polyamines in mediating malignant transformation and oncogene expression. Int J Biochem Cell Biol. 1999 Nov;31(11):1289-95. doi: 10.1016/s1357-2725(99)00098-9."
                },
                {
                    "pmid": "21147316",
                    "type": "RESULT",
                    "citation": "Liu R, Jia Y, Cheng W, Ling J, Liu L, Bi K, Li Q. Determination of polyamines in human urine by precolumn derivatization with benzoyl chloride and high-performance liquid chromatography coupled with Q-time-of-flight mass spectrometry. Talanta. 2011 Jan 15;83(3):751-6. doi: 10.1016/j.talanta.2010.10.039. Epub 2010 Nov 11."
                },
                {
                    "pmid": "16011702",
                    "type": "RESULT",
                    "citation": "Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-5. doi: 10.1111/j.1541-0420.2005.00311.x."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003922",
                    "term": "Diabetes Mellitus, Type 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7117",
                    "name": "Diabetes Mellitus, Type 1",
                    "asFound": "Type 1 Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000518",
                    "term": "Eflornithine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000014344",
                    "term": "Trypanocidal Agents"
                },
                {
                    "id": "D000000981",
                    "term": "Antiprotozoal Agents"
                },
                {
                    "id": "D000000977",
                    "term": "Antiparasitic Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000065108",
                    "term": "Ornithine Decarboxylase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M3859",
                    "name": "Eflornithine",
                    "asFound": "Blood samples taken",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4298",
                    "name": "Antiprotozoal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4294",
                    "name": "Antiparasitic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T13",
                    "name": "Ornithine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}